Axsome Therapeutics (AXSM) vs Supernus (SUPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Axsome Therapeutics (AXSM) has outperformed Supernus (SUPN) over the past year, losing 13.4% versus a loss of 36.9%. Over five years, AXSM leads with a +250.4% price change compared with -6.5% for SUPN. Axsome Therapeutics is the larger company by market cap ($6.80 billion vs $5.94 billion), about 1.1 times the size.
On valuation, Supernus trades at a lower forward P/E (7.1x vs 35.5x for Axsome Therapeutics). Supernus converts more of its revenue into profit, with a net margin of -5.4% versus -28.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | SUPN |
|---|---|---|
| Share price | $129.36 | $28.61 |
| Market cap | $6.80B | $5.94B |
| 1-day change | -4.66% | +0.92% |
| YTD return | -29.17% | -42.43% |
| 1-year return | -13.44% | -36.87% |
| 5-year return | +250.38% | -6.53% |
| Forward P/E | 35.47 | 7.15 |
| EPS (TTM) | $-3.03 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $718.95M |
| Revenue growth (YoY) | +65.55% | +8.63% |
| Net income (latest FY) | $-183.17M | $-38.55M |
| Gross margin | 92.56% | 89.63% |
| Operating margin | -26.12% | -8.66% |
| Net margin | -28.69% | -5.36% |
| 52-week high | $260.19 | $42.81 |
| 52-week low | $123.00 | $25.92 |
| Distance from 52-week high | -50.28% | -33.17% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +104.56% | +89.23% |
| Average volume | 865.33K | 2.77M |
| Shares outstanding | 52.60M | 207.72M |
| Employees | 1,390 | 827 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AXSM has outperformed SUPN by 23.4 percentage points over the past year.
- Supernus is more profitable, keeping -5.4 cents of every revenue dollar as net income versus -28.7 cents for Axsome Therapeutics.
- Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs +8.63%).
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,390 employees
About Supernus
SUPN stock →Supernus, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 827 employees
AXSM vs SUPN FAQ
Which is bigger, Axsome Therapeutics or Supernus?
Axsome Therapeutics (AXSM) is larger, with a market capitalization of $6.80B compared with $5.94B for Supernus (SUPN).
Which stock has performed better over the past year, AXSM or SUPN?
AXSM returned -13.44% over the past 12 months, compared with -36.87% for SUPN (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and Supernus in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.